Liraglutide, the long-acting glucagon-like peptide-1 (GLP-1) drug, was approved for weight loss in among pediatric patients aged 12 and older who are obese. Recently, manufacturer Novo Nordisk found in a sponsored study that children between the ages of 6 and 12—a younger population—were able to reduce their body mass index by 7.4% in a 56-week trial using daily liraglutide injections, as published in the New England Journal of Medicine. The trial of 92 children met …
Read More